Avanza Fonder AB Has $5.11 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Avanza Fonder AB increased its holdings in Regeneron Pharmaceuticals by 9.4% in Q2, now owning 9,737 shares valued at $5.1 million.
• Regeneron reported EPS of $12.89 for the quarter, exceeding estimates of $8.43, with revenue of $3.68 billion, up 3.6% year-over-year.
• After a recent quarterly dividend announcement, Regeneron’s annualized dividend yield stands at 0.6%, with a payout ratio of 8.87%.

Avanza Fonder AB increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,737 shares of the biopharmaceutical company's stock after acquiring an additional 838 shares during the period. Avanza Fonder AB's holdings in Regeneron Pharmaceuticals were worth $5,112,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sowell Financial Services LLC grew its stake in Regeneron Pharmaceuticals by 4.7% during the second quarter. Sowell Financial Services LLC now owns 583 shares of the biopharmaceutical company's stock worth $306,000 after buying an additional 26 shares during the period. CX Institutional raised its position in Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company's stock valued at $159,000 after purchasing an additional 22 shares during the period. Diversified Trust Co lifted its stake in shares of Regeneron Pharmaceuticals by 35.3% during the second quarter. Diversified Trust Co now owns 3,889 shares of the biopharmaceutical company's stock worth $2,042,000 after purchasing an additional 1,015 shares in the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $40,736,000. Finally, Grove Bank & Trust grew its stake in shares of Regeneron Pharmaceuticals by 36.7% in the second quarter. Grove Bank & Trust now owns 1,107 shares of the biopharmaceutical company's stock valued at $581,000 after buying an additional 297 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REGN. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Finally, Sanford C. Bernstein boosted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $6.72 during trading hours on Friday, hitting $591.99. The company's stock had a trading volume of 2,177,965 shares, compared to its average volume of 951,771. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,154.56. The company has a 50-day simple moving average of $567.77 and a 200 day simple moving average of $574.26. The firm has a market capitalization of $62.75 billion, a PE ratio of 14.92, a PEG ratio of 1.98 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the business posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.